Small molecule Rac inhibitors have been developed as potential cancer therapeutic agents [20–22], such as the Rac inhibitor EHT 1864, which specifically blocks Rac and GTP interaction and keeps Rac in an inactive state [23]. Here, AKT1 is linked to cancer.